(Amplify Public Affairs) Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer's pipeline analysis presented today at the Alzheimer's Association International Conference (AAIC) by ResearchersAgainstAlzheimer's (RA2), an UsAgainstAlzheimer's network.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2u4BvrU
No comments:
Post a Comment